These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27716874)

  • 1. Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up.
    Villani V; Merola R; Vidiri A; Fabi A; Carosi M; Giannarelli D; Marucci L; Maschio M; Carapella CM; Pace A
    Tumori; 2017 May; 103(3):255-260. PubMed ID: 27716874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
    Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
    Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
    Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
    Kaloshi G; Benouaich-Amiel A; Diakite F; Taillibert S; Lejeune J; Laigle-Donadey F; Renard MA; Iraqi W; Idbaih A; Paris S; Capelle L; Duffau H; Cornu P; Simon JM; Mokhtari K; Polivka M; Omuro A; Carpentier A; Sanson M; Delattre JY; Hoang-Xuan K
    Neurology; 2007 May; 68(21):1831-6. PubMed ID: 17515545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
    Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
    Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
    Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
    Rosenthal MA; Ashley DL; Cher L
    Intern Med J; 2002 Jul; 32(7):346-8. PubMed ID: 12088355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L; Vitanovics D; Afra D
    Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
    Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY
    J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
    Pace A; Vidiri A; Galiè E; Carosi M; Telera S; Cianciulli AM; Canalini P; Giannarelli D; Jandolo B; Carapella CM
    Ann Oncol; 2003 Dec; 14(12):1722-6. PubMed ID: 14630675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of palliative treatment with temozolomide in patients with high-grade gliomas.
    Ziobro M; Rolski J; Grela-Wojewoda A; Zygulska A; Niemiec M
    Neurol Neurochir Pol; 2008; 42(3):210-5. PubMed ID: 18651326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
    Ahluwalia MS; Xie H; Dahiya S; Hashemi-Sadraei N; Schiff D; Fisher PG; Chamberlain MC; Pannullo S; Newton HB; Brewer C; Wood L; Prayson R; Elson P; Peereboom DM
    J Neurooncol; 2015 Mar; 122(1):111-9. PubMed ID: 25534576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
    Rudà R; Pellerino A; Pace A; Carapella CM; Dealis C; Caroli M; Faedi M; Bello L; Migliore E; Marchese G; Bertero L; Cassoni P; Soffietti R
    J Neurooncol; 2019 Oct; 145(1):115-123. PubMed ID: 31556015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide for recurrent low-grade spinal cord gliomas in adults.
    Chamberlain MC
    Cancer; 2008 Sep; 113(5):1019-24. PubMed ID: 18615600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
    Wick W; Platten M; Meisner C; Felsberg J; Tabatabai G; Simon M; Nikkhah G; Papsdorf K; Steinbach JP; Sabel M; Combs SE; Vesper J; Braun C; Meixensberger J; Ketter R; Mayer-Steinacker R; Reifenberger G; Weller M;
    Lancet Oncol; 2012 Jul; 13(7):707-15. PubMed ID: 22578793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.
    Kaloshi G; Sierra del Rio M; Ducray F; Psimaras D; Idbaih A; Laigle-Donadey F; Taillibert S; Houillier C; Dehais C; Omuro A; Sanson M; Delattre JY; Hoang-Xuan K
    J Neurooncol; 2010 Dec; 100(3):439-41. PubMed ID: 20464625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
    Beauchesne P; Quillien V; Faure G; Bernier V; Noel G; Quetin P; Gorlia T; Carnin C; Pedeux R
    Int J Cancer; 2016 Mar; 138(6):1538-44. PubMed ID: 26501997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
    Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.